MUC-1和CD44V6在乳腺癌中的表达及其意义

 目的　探讨MUC-1和CD44V6在乳腺癌中的表达及其意义。方法　采用免疫组织化学二步法检测93例不同病理类型的乳腺癌中MUC-1和CD44V6的表达，并进行相关分析。结果　MUC-1、CD44V6在93例乳腺癌中的阳性表达率分别为71.0 %（66／93）和63.4 %（59／93）。MUC-1的表达在不同类型、临床分期及体积的乳腺癌中，差异均无统计学意义（均P＞0.05），而在不同组织学分级（14.3 %、69.4 %、100.0 %）、有无淋巴结转移（22.9 %、100.0 %）的乳腺癌中，则差异有统计学意义（χ2值分别为36.147、63.047，均P＜0.0001）；CD44V6的表达在不同组织学类型、体积及组织学分级的乳腺癌中，差异均无统计学意义（均P＞0.05），而在不同临床分期（6.3 %、64.6 %、93.1 %）、有无淋巴结转移（20.0 %、89.7 %）的乳腺癌中，则差异有统计学意义（χ2值分别为9.507、45.662，均P＜0.05）。结论　MUC-1和CD44V6在乳腺癌的发生、发展中起着重要的调控作用。MUC-1和CD44V6的高表达与乳腺癌的生物学行为密切相关，对判断乳腺癌的预后和指导临床治疗均有重要意义。

Expression of MUC-1 and CD44v6 in breast carcinoma and its significance

Objective To investigate the expression of MUC-1 and CD44v6 in breast carcinoma and its diagnostic value. Methods 93 cases of breast carcinoma were examined by immunohistochemical method for MUC-1 and CD44v6. Results The positive rates of MUC-1 and CD44v6 were 71.0 % （66/93） and 63.4 % （59/93）, respectively. The expression of MUC-1 in breast carcinoma was correlated with histologic differentiation （14.3 %, 69.4 %, 100.0 %） and lymph node metastasis （22.9 fie, 100.0 %） （χ2 = 36.147, 63.047, both P 〈 0.0001）, but had no relationship with the type of breast carcinoma, tumor clinical stages, and tumor size （all P 〉 0.05）. The expression of CD44v6 in breast carcinoma was correlated with tumor clinical stages （6.3 %, 64.6 %, 93.1%） and lymphnode metastasis （20.0 %, 89.7 %） （χ2 = 9.507, 45.662, both P＇〈 0.05）, but had no relationship with tumor type, tumor clinical stages and tumor size （all P 〉 0.05）. Conclusion MUC-1 and CD44v6 may play important roles in the development of breast carcinoma and the biologic behavior of breast carcinoma may be closely related with over expression of MUC-1 and CD44v6 protein. MUC-1 and CD44v6 can be used to predict the prognosis and direct the treatment of breast carcinoma.